Study guide
8.2 Privacy, Confidentiality and Appropriate Access
ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Format, Eligibility and Registration
1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions
2 Chapter 2: CRA Responsibilities and Study Planning
2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy
3 Chapter 3: Protocols, Endpoints and Trial Design
3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs
4 Chapter 4: Bias Control, Blinding and Product Information
4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates
5 Chapter 5: Estimands and Device Instructions
5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training
6 Chapter 6: Ethical Foundations and Independent Oversight
6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review
7 Chapter 7: Ethics Communication and Informed Consent
7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates
8 Chapter 8: Recruitment, Retention and Confidentiality
8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access
9 Chapter 9: Safety Definitions and Classification
9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information
10 Chapter 10: Safety Detection, Reporting and Oversight
10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight
11 Chapter 11: Follow-Up, Adherence and Conflicts
11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments
12 Chapter 12: Development Stages and Product Management
12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response
13 Chapter 13: Accountability, Integrity and Regulatory Status
13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting
14 Chapter 14: Current GCP Principles and Delegation
14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority
15 Chapter 15: Oversight, Protocol Control and Amendments
15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution
16 Chapter 16: Implementation and Trial Responsibilities
16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles
17 Chapter 17: Quality Planning, Root Causes and CAPA
17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification
18 Chapter 18: Risk Assessment and Monitoring Methods
18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review
19 Chapter 19: Quality Metrics, Plans and Communication
19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication
20 Chapter 20: Site Qualification and Readiness
20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release
21 Chapter 21: Initiation, Equipment and Supplies
21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies
22 Chapter 22: Samples, Diagnostics and Financial Feasibility
22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility
23 Chapter 23: Interim Monitoring and Reporting
23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports
24 Chapter 24: Essential Records, Audits and Findings
24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning
25 Chapter 25: Close-Out, Retention and Destruction
25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access
26 Chapter 26: Source Records and Good Documentation
26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context
27 Chapter 27: Electronic Systems, Metadata and Queries
27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning
28 Chapter 28: Dataset Finalisation and Critical Data
28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings
8.2 Privacy, Confidentiality and Appropriate Access
Key Takeaways Explain This Topic AI
Coded participant data are not necessarily anonymous.
Monitoring access should be attributable, appropriate and confidentiality-conscious.
Privacy incidents require prompt controlled response and evidence preservation.
Last updated: October 2026
Privacy, Confidentiality and Appropriate Access
Privacy concerns access to a person's information and circumstances; confidentiality concerns protecting information entrusted to the research team. Monitoring needs access to relevant records, but that need does not remove restrictions on use, copying or disclosure. E6(R3) requires protection of participant-identifying information throughout the trial and data lifecycle, consistent with applicable requirements.
The participant should understand confidential direct access by authorised monitors, auditors, authorities and, where applicable, the ethics committee. The investigator/institution uses an unambiguous code for data reported to the sponsor and retains the ability to link it to the participant. A coded dataset is not necessarily anonymous: someone may still be able to re-identify the person. Treat that distinction seriously when sharing data or discussing cases.
Designing appropriate access
Before monitoring, establish which records contain relevant source information, who authorises access, what the monitor can see and what restrictions apply. Site and sponsor processes should support the agreed review while limiting inappropriate access. A monitor account should be attributable and suited to the task. Never use a coordinator's or investigator's login to avoid an access delay.
For paper records, control the workspace, unattended documents, copying and return. For electronic records, consider participant scoping, permissions, download rights, access expiration and audit logs. Remote review adds questions about network security, viewing location, screen sharing and copies retained on devices. A convenient screenshot can create an uncontrolled identifiable record outside the approved repository.
What should travel to the sponsor?
Information Typical handling concern Practical check
Coded eCRF data Correct participant code and authorised fields Check coding and relevant collection instructions
Participant identity linkage Usually controlled by the investigator/institution Preserve secure traceability without routine sponsor dissemination
Medical records needed for safety follow-up Necessary details may coexist with identifiers Use the authorised secure, privacy-conscious process
Recruitment or screening logs May contain information about people not enrolled Limit collection/access to what is justified and permitted
Electronic audit information Can reveal user identity and accidental personal information Preserve needed metadata while controlling disclosure
Do not send a whole identifiable chart merely because one result is needed. Conversely, excessive redaction can remove information needed to assess a safety event. The responsible functions should establish an appropriate method balancing necessary review, confidentiality and applicable requirements. A CRA should escalate an unresolved access conflict rather than decide that either privacy or monitoring always overrides everything else.
An access scenario
A site offers read-only access to all hospital patients so the monitor can locate a few trial records. The CRA should seek a more appropriately scoped method and document the concern. If the system cannot technically restrict access to particular patients, the sponsor and institution should assess and mitigate the risk under their procedures. The monitor's behaviour and permissions still need controls; an imperfect interface is not permission to browse unrelated records.
Now suppose the site offers only a printed summary without certification or supporting context. Evaluate whether the agreed review can be achieved with originals, certified copies or another suitable arrangement. ICH does not universally require live EHR access, but the data must remain verifiable. Obtain a documented resolution that preserves both confidentiality and adequate oversight.
Incident response
An identifiable document sent to the wrong recipient requires prompt action. Stop further inappropriate distribution, restrict access where possible, notify the designated privacy/security and quality functions and preserve evidence. Determine what was sent, when, to whom, whether it was accessed and what containment occurred. Follow applicable assessment and notification requirements rather than assuming every incident has the same statutory deadline.
Do not independently destroy a source record, delete an audit trail or quietly replace a file to make the incident disappear. E6(R3) recognises rare justified audit-trail changes, such as removal of accidentally entered personal information, only with a log of the action and justification. The incident record should support reconstruction and prevention even when the exposed content is removed through a controlled process.
Continuing protection after closure
Confidentiality persists during archiving, service-provider changes and destruction. Ensure access remains authorised, records remain retrievable and any migration preserves needed information and metadata. Notify the responsible party when staff leave or roles change; remove access appropriately while retaining attribution for past work. A shared former employee account cannot be made compliant by changing its display name.
Country-specific privacy examples appear in the ECO tasks, but ACRP states that country-specific frameworks are not tested. Practise the underlying skill: recognise identifying information, confirm appropriate access and use, protect it during transfer and storage, and respond transparently when protection fails. The same reasoning applies whether the source is paper, an EHR, a participant application or a laboratory portal.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , WMA Declaration of Helsinki, 2024 , ICH E11(R1) .